Home > Journals > Esperienze Dermatologiche > Past Issues > Esperienze Dermatologiche 2015 June;17(2) > Esperienze Dermatologiche 2015 June;17(2):81-5





A Journal on Dermatology

Journal of Istituto Dermatologico San Gallicano
Official Journal of the Associazione Dermatologi Ospedalieri Italiani - A.D.O.I.
Indexed/Abstracted in: EMBASE, Scopus



Esperienze Dermatologiche 2015 June;17(2):81-5

language: English

Evaluation of emulgel containing nicotinamide 5%, azeloyl diglycinate 5%, coenzyme q10, hyaluronic acid and phospholipids in treatment of mild-moderate acne

Fabbrocini G., Capasso C., Monfrecola G.

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Federico II of Naples, Naples, Italy


Acne is a chronic inflammatory dermatosis affecting approximately up to 85% of 11-30 year-olds. According to the evolution, acne can be classified as mild, moderate, or severe. Topical treatment is the first choice in mild and moderate acne, whereas systemic therapy is used to treat severe and moderate cases. Taken together, there are several conventional treatment options, but each may have use-limiting side effects that diminish the patient compliance, compromising the efficacy of the therapy. New molecular and clinical studies have advanced knowledge in areas; therefore, alternative treatments, such as nicotinamide, azelaic acid derivatives, coenzyme Q10, have been suggested for treatment of the acne vulgaris. According to the different actions of these compounds that can fight the oxidative stress in acne, the aim of this study is to evaluate clinical activity of these compounds.

top of page

Publication History

Cite this article as

Corresponding author e-mail